Oncologica is a leading contract research organization specializing in small and large end-to-end bioinformatic CRO laboratory services. We offer bioanalytical clinical contract research to aid drug and targeted medicine innovation through our expertise in genetic cell-based assays, molecular biomarkers and immunogenicity services.
We work as a collaborative CRO partner to deliver integrated bioanalytical contract research solutions for your genomic sequencing needs. We excel in bioinformatics contract research where extensive sequencing capabilities and accurate detection of variants are required.
- Human genetics research partner
- Outsource genetic studies
- Bioanalytical pre-clinical contract research
- Drug manufacturing bioanalytical research
- UK based genetic CRO
Genomic Sequencing Services
Oncologica sequencing capabilities are suitable for:
- Rare disease studies
- Cancer exome analysis
- Complex disease genomics
- Translational research
RNA Sequencing Services
Our highly experienced bioinformatics team utilise lab sequencing and a leading genomic data library, for analysis and interpretation of:
- Gene expression
- Transcriptome analysis
- RNA sequencing services
Sequencing for the Microbiome
Our wide range sequencing capabilities allows our researchers to sequence all given genomic DNA in a complex sample. This provides valuable insights into community biodiversity and function. The sequencing data can be used for metagenomic assembly, function and gene resistance profiling.
Bacterial RNA Sequencing
Oncologica Sequencing provides bacterial RNA sequencing, which can identify and compare bacterial community in a sample by sequencing regions of the bacterial 16s rRNA gene.
- Access Oncologica’s large database of genomic data
- Undertake bioinformatic analysis for taxonomy assignment
Cdc6 protein causes premature entry into S phase in a mammalian cell-free system
EMBO J. 1998 Dec 15;17(24):7219-29.
Stoeber K, Mills AD, Kubota Y, Krude T, Romanowski P, Marheineke K, Laskey RA, Williams GH.
Improved cervical smear assessment using antibodies against proteins that regulate DNA replication
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7.
Williams GH, Romanowski P, Morris L, Madine M, Mills AD, Stoeber K, Marr J, Laskey RA, Coleman N.
The Hormonal Receptor Status of Uterine Carcinosarcomas (Mixed Mullerian Tumours): an Immunohistochemical study
Journal of Clinical Pathology, April 1997, Vol. 50: No.4, p328-331 DOI: https://dx.doi.org/10.1136%2Fjcp.50.4.328
A.C. Ansink, P.A. Cross, P. Scorer et al (1997)